ENDXENoUS GR-HORMONE (GH) SECRETIOR AND RESPONSE TO METHIONINE-GH THERAPY IN GROWI7I RETARDED CHILDREN.
In an open multi-center study 30 short prepubertal children (21 boys, 9 girls) were randmly divided into a treatment group (n=20) and a control group (n=10). Inclusion criteria were: age above 6 years; bone age below 8 "years" for girls and 10 "years" for boys; height SDS <-2.5; growth velocity <P25 for age or bone age; peak plasm GH in standard provocation tests >15 mU/1. In the treatment group endogenous GII-secretion was assessed by a 24-hour GH-profile, arginine infusion, exercise test, G I (1-29)-test and plasm SM-C/IGF-I. Met-GH was administered s.c. once a day in a dosage of 2 1u/m2 body surface. The integrated GI1 concentration over 24 hours (ICGfI) ranged between 2.2 and 13.4 mIU/I (median 5.6). In 58% of the children ICGH was <6 mIU/l (3ng/ml), the reported upper limit of "neurosecretory dysfunction". Mean (+ SD) growth velocities were: Baseline 0 -3m 3 -6 m 6 -9 m met-GH 4.4 2 1.5 8.2 5 2.3 6.6 2 2.0 6.5 2 2 . 2 control 4.5 + 0.8 4.4 + 1.4 3.8 + 2.1 4.0 + 1.4 12 Children had a growth response >2 cm/year. There were no significant correlations between the growth response versus ICGH and SM-C/IGF-I. Anti-GH antibodies were positive in 56% of the children at 9 months, in 4 of them with a high binding capacity. 
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CONTlllBUTION OF NSE AND FWQUENCY TO TllE TIlEKAPEUlIC EFFECT OF Gll.
We treatcd 42 GI1 insufficient prepubertal children aged 3-12 years u~t t > 12 i u biosynthetic GH per weck ior 1 year-after pretreatment observation of 1 year. Group 1 (n=13) received 1, i u GH 3 days per weck, Group 2 (n=21) 2 i u GH o days per week and Group 3 ("4) 1 i u GI1 twice daily 6 days per week. Between groups, pretreatment age (CA), bone age (BA) and auxological parameters were identical.
Height velocity improved (p<0.001) i n a l l groups with a positive trend i n the tligher frequency regimens. Changes i n height velocity (IIV) SDS .03 These data showed that GI1 dose and frequency of administration are rclevant to the response to treatment with 611, but pretreatment IlVSDS i s the dominant factor i n predicting i t s aagnitude. Slxtcen p n t l c n t s (15m,l T) LVILII (jrowtli l~o r n i o n e (C I l l (IDLrcalerl w l t l~ m c l h~o i~y l G I I (Somnl.rcm, I 11ly) I'or one y r a r Lliempy i v l l l i p11.1~1Lnry G II. 11 earl rlurnl.~on 111 Lreat III er~L w l t h pituiLary T; ll was 5,513.3 yrs (x2SD), tliin LrcnLrn cril. was lntc:~.r~iliLr:C f o r 0,4 y r s on ;,vernqc b e f o r e onset o f Sornntrem Lliern[,y. AL t t i x t~r n c c l i r o n r~l o q~r : i l nrje was 15,1+5,l? -yrs, t~o r i c nqe wn:; 12,3+2,7 yrs an11 t~c~c l l i l w:~:; -2,8+1,1 SD. Som:jl.rem dose w;l :; fl,lhU/kq 1.m. 3 L~i n c s weekly. T l~c proLnc11l was approve11 by Llic c:tli~r;il r n m ~n l L l c u :~n d rrlformecl crl~isrril was o b t a~n c d . GrowLh .~e l o c l t l c s d u r~n q Lhc vnrlous pcr~r~<l:; were: 1; 1: ; 1 year on p11.111t.nry Gli: 7,3+1,9 -cm/yr; ~n L c r v a l w~l.l~ouL Lrcai ment: 2 , j t -0,9 cm/yr; hrsl. h month:; o n SomaLrem: 7,5+1,2 cm/yr; :;er:ond 6 rr1<ir11113 o n Somatrcm: 6,6+ 1,9 cm/yr. 13o11e-aqe-rcl a&.~i q r o w t h velocity clur~rirj SomaLrem LreaLmenl was l i~q h i n r l i c a t~n q rnLc11 up q r o w l l~ even lrl Lllis advanced aqe group. Bone nqe dl11 noL proceerl ~l n r l i~l y tlurlnrj tre:~l men1 (0,96 "year!;"/yr).
Tlic h c~q h t d e r~c~L dccreasccl f r o m -2,O Lo -2,l 51) .
There was no l n d~r a t~o n o f qlucose in1 olcrancc. I'l can som nLo m c d l n ct11l-c:cnLra?~ons incrensecl siqnlficantly. G II-anttbodles demonslrated a shrllit P. Nilton*, L. Widlund*, 0. Guilbaud* (Introd. by M. Ritzen) . min for the 6 phase between 60-120 min. The metabolic clearance rate varied between 82-1 39 ml/min/ni2. 8 + 3 volunteers wzre given the s a w dose, 0.1 IU/kg BW, S.C. in the morning after 12 hours' fasting. They were resting in bed during the whole e m r i m n t , i.e. 12 hours. Lunch and dinner at 5 and 10 hours, respectively. Blccd samples every 15 min during the first 6 I?ours, every 30 m i n the next 2 hours and every 60 min during the remaining 4 hours. The peak GI Concentration, Cmax, was 53t4.2 mU/1 with tof 5.3i0.6 hours. After S.C. dosing the s e m concentration of GFI declined with a half-life of 248155 min. This half-life, considerably longer than the half-life found after i.v. aihninistration, probably reflects the absorption which thus is the rate limiting step in this way of administration. 
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Z u r l c h ( S w i t z e r l a n d ) ? , O i v i s~o n o f G e n e t~c s V a n d e r b i l t --U n i v e r s i t y , Nashville TN, (U5A)3 DISPARITY OF PITUITARY AND BIOSYNTHETIC GROWTH tlORMONL I N ANTIGENICITY AND GROWTll RESPONSE OBSERVED I N TWO BROTIiERS WlTll ISOLATED GI 4 DEFICIENCY (IGIID) TYPE IA.
Two boys w~t h IGHD due t o GII-N gene d e l e t l o n d e v e l o p e d a n t l b od r e s (Ab) t o exogenous GII. The younger boy A ( a g e 3 y , h e~y h t -5.8SD a t s t a r t o f R) w l t h h l g h Ab t l L r e s d~d n o t grow d u r~r i g t h c r a p y w l t h plt-GII. A f t e r 2 y w l t h o u t Rxand a d e c r e a s e o f Ab t l t r e s h e showed a tremendous y r o w t l i response t o t r e a t m e n t w l t h bio-met t i l o n y l -G H and o n l y a moderate r l s e o f Ab t l t r e s . The o l d e r boy B
( a g e 9.5 y , h e l g h t -7 . 8 9 ) w i t h low Ab t i t r e s showed a normal g r o w t h r a t e d u r l n r i t r e a t m e n t w l t h ~l t -G l i and b l o -m e t h l o n v l -G H . h c a t c h a r d a n a l y s i s w l t h bio-methionyl-GI4 showed a l o w e r b i n d l n g c a p a c i t y . T h i s , and t h e l e s s e r a n t l g e n l c i t y o f blo-GH ma e x p l a l n t h e t t i e r a p e u t i c a l success i n t h e s e 2 p a t i e n t s with IGHD b e IA.
JE Toublanc, P G a r n i e r , C Couprie*, J L Chaussain, JC Job
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H o p i t a l S a i n t -V i n c e n t de P a u l , 75014 P a r i s , France EFFECT OF LHRH ANALOGUE I N PUBERTAL PATIENTS WITH ISOLATED GROWTH HORMONE DEFICIENCY. I n i s o l a t e d GH d e f i c i e n c y , a t o o i n s u f f i c i e n t h e i g h t a t o n s e t o f a p u b e r t y l e a d s t o r e d u c e d a d u l t h e i g h t . I n o r d e r t o p r e v e n t t h i s we have t r i e d t h e e f f i c i e n c y o f LHRH analogue i n a s s o c i a t~n n w i t h GH i n such cases.
L o n g -a c t i n g T r p 6 LHRH analogue (LHRHa) was used i n 4 male p a t i e n t s aged 12 t o 16 y e a r s , t r e a t e d w i t h hGH 20 I U / k g / y r f r o m 1 t o 6 y e a r s f o r i s o l a t e d GH d e f i c i e n c y . LHRHa was i n j e c t e d IM m o n t h l y ( 3 . 7 mg i n 2 p a t i e n t s , 1 . 8 i n 2 ) f r o m t h e o n s e t o f 
